Griffin Asset Management Inc. acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 3,531 shares of the biopharmaceutical company’s stock, valued at approximately $1,579,000.

Several other institutional investors also recently added to or reduced their stakes in REGN. Harding Loevner LP increased its position in Regeneron Pharmaceuticals by 589.2% in the third quarter. Harding Loevner LP now owns 3,663,548 shares of the biopharmaceutical company’s stock worth $286,619,000 after purchasing an additional 3,131,966 shares during the last quarter. Janus Henderson Group PLC increased its position in Regeneron Pharmaceuticals by 15,495.4% in the second quarter. Janus Henderson Group PLC now owns 1,562,970 shares of the biopharmaceutical company’s stock worth $767,637,000 after purchasing an additional 1,552,948 shares during the last quarter. Jennison Associates LLC increased its position in Regeneron Pharmaceuticals by 74.1% in the second quarter. Jennison Associates LLC now owns 1,292,863 shares of the biopharmaceutical company’s stock worth $634,977,000 after purchasing an additional 550,247 shares during the last quarter. FMR LLC increased its position in Regeneron Pharmaceuticals by 6.3% in the second quarter. FMR LLC now owns 7,039,884 shares of the biopharmaceutical company’s stock worth $3,457,569,000 after purchasing an additional 416,192 shares during the last quarter. Finally, Old Mutual Global Investors UK Ltd. increased its position in Regeneron Pharmaceuticals by 500,446.2% in the third quarter. Old Mutual Global Investors UK Ltd. now owns 325,355 shares of the biopharmaceutical company’s stock worth $145,472,000 after purchasing an additional 325,290 shares during the last quarter. Hedge funds and other institutional investors own 66.67% of the company’s stock.

Get Regeneron Pharmaceuticals Inc. alerts:

Several brokerages recently weighed in on REGN. BTIG Research restated a “buy” rating and issued a $520.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, November 22nd. J P Morgan Chase & Co restated a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, August 15th. Canaccord Genuity set a $522.00 price target on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, August 14th. Citigroup cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $480.00 to $380.00 in a research report on Friday, December 1st. Finally, Piper Jaffray Companies restated an “overweight” rating and issued a $540.00 price target on shares of Regeneron Pharmaceuticals in a research report on Friday, September 29th. Two analysts have rated the stock with a sell rating, sixteen have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $467.84.

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) opened at $381.32 on Tuesday. Regeneron Pharmaceuticals, Inc. has a one year low of $340.09 and a one year high of $543.55. The stock has a market cap of $40,910.63, a price-to-earnings ratio of 32.97, a PEG ratio of 1.50 and a beta of 1.53. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.07 and a current ratio of 3.63.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.83 by $0.16. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The company had revenue of $1.50 billion during the quarter, compared to analyst estimates of $1.45 billion. During the same period in the prior year, the firm earned $3.13 earnings per share. The firm’s revenue for the quarter was up 23.0% compared to the same quarter last year. sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 13.55 EPS for the current fiscal year.

In related news, Director Michael S. Brown sold 1,500 shares of the company’s stock in a transaction dated Thursday, October 5th. The shares were sold at an average price of $475.00, for a total value of $712,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Charles A. Baker sold 2,000 shares of the company’s stock in a transaction dated Friday, September 29th. The stock was sold at an average price of $450.00, for a total transaction of $900,000.00. Following the completion of the sale, the director now directly owns 11,000 shares of the company’s stock, valued at $4,950,000. The disclosure for this sale can be found here. 10.80% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION WARNING: “Griffin Asset Management Inc. Acquires Shares of 3,531 Regeneron Pharmaceuticals, Inc. (REGN)” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/12/12/griffin-asset-management-inc-acquires-shares-of-3531-regeneron-pharmaceuticals-inc-regn.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.